Long-term use of foscarnet is associated with an increased incidence of acute kidney injury in hematopoietic stem cell transplant patients: A retrospective observational study.
acute kidney injury
foscarnet
hematopoietic stem cell transplantation
long-term use
renal function
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
revised:
13
01
2022
received:
09
11
2021
accepted:
20
01
2022
pubmed:
4
2
2022
medline:
8
4
2022
entrez:
3
2
2022
Statut:
ppublish
Résumé
Foscarnet is an important drug for the treatment of cytomegalovirus infection in patients undergoing hematopoietic stem cell transplantation (HSCT). Foscarnet is often discontinued because of the development of acute kidney injury (AKI). Thus, the identification of factors leading to the development of AKI is beneficial. This study aimed to investigate the incidence of AKI and the factors influencing AKI development in HSCT patients treated with foscarnet. This was a retrospective observational study. Patients who underwent HSCT and received foscarnet at the Department of Hematology, Osaka City University Hospital, were identified from medical records. The patients were classified into AKI and non-AKI groups, and the risk factors associated with AKI were evaluated. For continuous variables, receiver-operating characteristic (ROC) curve analysis was used to calculate the optimal cutoff value. Thirty-five patients (47 cases) were assigned to the AKI (51.1%, 24/47) and non-AKI groups (48.9%, 23/47). The AKI group had a significantly longer foscarnet administration period than the non-AKI group (p = 0.049). The appropriate cutoff value for the foscarnet administration period using the ROC curve was 27 days. The incidence of AKI was significantly higher in cases who received foscarnet for more than 27 days (11/14, 78.6%) compared to those who received less than 27 days (13/33, 39.4%) (odds ratio: 5.64, 95% confidence interval 1.32-24.2, p = 0.024). The incidence of AKI was 51.1% in HSCT patients treated with foscarnet, and foscarnet administration for more than 27 days may be associated with the incidence of AKI.
Sections du résumé
BACKGROUND
BACKGROUND
Foscarnet is an important drug for the treatment of cytomegalovirus infection in patients undergoing hematopoietic stem cell transplantation (HSCT). Foscarnet is often discontinued because of the development of acute kidney injury (AKI). Thus, the identification of factors leading to the development of AKI is beneficial. This study aimed to investigate the incidence of AKI and the factors influencing AKI development in HSCT patients treated with foscarnet.
METHODS
METHODS
This was a retrospective observational study. Patients who underwent HSCT and received foscarnet at the Department of Hematology, Osaka City University Hospital, were identified from medical records. The patients were classified into AKI and non-AKI groups, and the risk factors associated with AKI were evaluated. For continuous variables, receiver-operating characteristic (ROC) curve analysis was used to calculate the optimal cutoff value.
RESULTS
RESULTS
Thirty-five patients (47 cases) were assigned to the AKI (51.1%, 24/47) and non-AKI groups (48.9%, 23/47). The AKI group had a significantly longer foscarnet administration period than the non-AKI group (p = 0.049). The appropriate cutoff value for the foscarnet administration period using the ROC curve was 27 days. The incidence of AKI was significantly higher in cases who received foscarnet for more than 27 days (11/14, 78.6%) compared to those who received less than 27 days (13/33, 39.4%) (odds ratio: 5.64, 95% confidence interval 1.32-24.2, p = 0.024).
CONCLUSION
CONCLUSIONS
The incidence of AKI was 51.1% in HSCT patients treated with foscarnet, and foscarnet administration for more than 27 days may be associated with the incidence of AKI.
Substances chimiques
Foscarnet
364P9RVW4X
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13804Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients? Blood. 2009;113:5711-5719.
Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: Clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008;47:303-327.
Ljungman P, de la Camara R, Cordonnier C, et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 2008;42:227-240.
Pierce B, Richardson CL, Lacloche L, Allen A, Ison MG. Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: a single-center study. Transpl Infect Dis. 2018;20:e12852.
Lopes JA, Jorge S, Neves M. Acute kidney injury in HCT: An update. Bone Marrow Transplant. 2016;51:755-762.
Summary of recommendation statements. Kidney Int Suppl. 2012;2:8-12.
Ota R, Hirata A, Noto K, et al. Relationship between serum calcium and creatinine in hematopoietic stem cell transplantation patients treated with foscarnet. Int J Clin Pharmacol Ther. 2020;58:274-281.
Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: Defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367-369.
Philipponnet C, Michel PA, Daudon M, Brocheriou I, Boffa JJ. Intravascular foscarnet crystal precipitation causing multiorgan failure. Am J Kidney Dis. 2015;65:152-155.
Maurice-Estepa L, Daudon M, Katlama C, et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis. 1998;32:392-400.
Zanetta G, Maurice-Estepa L, Mousson C, et al. Foscarnet-induced crystalline glomerulonephritis with nephrotic syndrome and acute renal failure after kidney transplantation. Transplantation. 1999;67:1376-1378.
Aweeka FT, Jacobson MA, Martin-Munley S, et al. Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:350-357.